AI-Based Mobile Intervention on Medication Non-Adherence and Transition
Sponsor: University of Central Florida
Trial Details
| Condition | Epilepsy, Seizure |
| Intervention | Medilepsy® Chatbot AI-Enhanced; Medilepsy® Chatbot Standard |
| Phase | NA |
| Status | Recruiting |
| Participants | 200 |
| Est. Completion | 1 Dec 2026 |
| Last Updated | 29 May 2026 |
Primary Outcome
Examine the effect of Medilepsy® with and without responsible AI design on medication adherence.
Eligibility Criteria
Inclusion Criteria
Inclusion Criteria: * Diagnosed with epilepsy * Currently prescribed anti-seizure medicine (ASMs) * Identified as part of an underserved population, defined as meeting at least one of the following: member of a racial or ethnic group historically underrepresented in research or healthcare or low-income status (e.g., eligible for public assistance or government-subsidized health coverage) * Are between 14-17 years old and able to provide assent, with a parent or LAR present to receive app notifications throughout the study * Are between 18-24 years old and able to provide informed consent * Able to read, speak, and write in English * Resides in Florida * Receive outpatient medical services Exclusion Criteria: * They do not own a mobile device with internet access. * They have a history of severe intellectual disability. * They are unable to operate a mobile device (keyboard or touchscreen). * Reside in an in-patient setting. * Adults unable to consent. * Pregnant women (excluded because pregnancy is not relevant to the study focus). * Prisoners.
Trial Sites
Countries
This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service